The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat

European Journal of Pharmacology

Volumn 741, Issue , 2014, Pages 254-263

  Hansen, Henrik H ^a   Hansen, Gitte ^a   Paulsen, Sarah ^a   Vrang, Niels ^a   Mark, Michael ^b   Jelsing, Jacob ^a   Klein, Thomas ^b  

^a Gubra ApS   (Denmark)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

DPP IV inhibitor; Dynorphin; GLP 1; Linagliptin; Obesity; Weight loss

Indexed keywords

ANOREXIGENIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; LINAGLIPTIN; PURINE DERIVATIVE; QUINAZOLINE DERIVATIVE; SUGAR INTAKE;

ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; ANIMAL; BODY WEIGHT; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; LIPID DIET; MALE; METABOLISM; OBESITY; PHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT; SUGAR INTAKE; WEIGHT REDUCTION;

ANIMALS; APPETITE DEPRESSANTS; BODY WEIGHT; DIET, HIGH-FAT; DIETARY SUCROSE; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE 1; MALE; OBESITY; PURINES; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; WEIGHT LOSS;

EID: 84906982768     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.08.010     Document Type: Article

References (49)

1. J.G. Barrera, D.A. D'Alessio, and D.J. Drucker Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats Diabetes 58 2009 2820 2827
2. I. Baumgartner, G. Pacheco-López, and E.B. Rüttimann Hepatic-portal vein infusions of glucagon-like peptide-1 reduce meal size and increase c-Fos expression in the nucleus tractus solitarii, area postrema and central nucleus of the amygdala in rats J. Neuroendocrinol. 22 2010 557 563
3. S. Bi, B.M. Robinson, and T.H. Moran Acute food deprivation and chronic food restriction differentially affect hypothalamic NPY mRNA expression Am. J. Physiol. Regul. Integr. Comp. Physiol. 285 2003 R1030 R1036
4. A.W. Bruijnzeel kappa-Opioid receptor signaling and brain reward function Brain Res. Rev. 62 2009 127 146
5. P.K. Chelikani, A.C. Haver, and R.D. Reidelberger Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats Am. J. Physiol. Regul. Integr. Comp. Physiol. 288 2005 R1695 R1706
6. T.A. Czyzyk, R. Nogueiras, and J.F. Lockwood kappa-Opioid receptors control the metabolic response to a high-energy diet in mice FASEB J. 24 2010 1151 1159
7. S.L. Dickson, R.H. Shirazi, and C. Hansson The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors J. Neurosci. 32 2012 4812 4820
8. A.M. Dossat, R. Diaz, and L. Gallo Nucleus accumbens GLP-1 receptors influence meal size and palatability Am. J. Physiol. Endocrinol. Metab. 304 2013 E1314 E1320
9. A.M. Dossat, N. Lilly, and K. Kay Glucagon-like peptide 1 receptors in nucleus accumbens affect food intake J. Neurosci. 31 2011 14453 14457
10. D.J. Drucker, and M.A. Nauck The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 2006 1696 1705
11. E.P. Guedes, A. Hohl, and T.G. de Melo Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment Diabetol. Metab. Syndr. 5 2013 25
12. G. Hansen, J. Jelsing, and N. Vrang Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats Acta Pharmacol. Sin. 33 2012 194 200
13. M.R. Hayes, S.E. Kanoski, and A.L. Alhadeff Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats Obesity (Silver Spring) 19 2011 1342 1349
14. J.J. Holst, and C.F. Deacon Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors Diabetologia 48 2005 612 615
15. J.J. Holst, C. Orskov, and O.V. Nielsen Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut FEBS Lett. 211 1987 169 174
16. J.J. Holst The physiology of glucagon-like peptide 1 Physiol. Rev. 87 2007 1409 1439
17. K. Hunter, and C. Hölscher Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis BMC Neurosci. 13 2012 33
18. J. Jelsing, N. Vrang, and G. Hansen Liraglutide: short-lived effect on gastric emptying - long lasting effects on body weight Diabetes Obes. Metab. 14 2012 531 538
19. J. Jelsing, P.J. Larsen, and N. Vrang The effect of leptin receptor deficiency and fasting on cannabinoid receptor 1 mRNA expression in the rat hypothalamus, brainstem and nodose ganglion Neurosci. Lett. 463 2009 125 129
20. L. Jessen, B.A. Aulinger, and J.L. Hassel Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4 Endocrinology 153 2012 5735 5745
21. R.B. Jones, S.P. Vickers, and S.C. Cheetham Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats Eur. J. Pharmacol. 729 2014 59 66
22. S.E. Kanoski, S.M. Fortin, and M. Arnold Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4 Endocrinology 152 2011 3103 3112
23. S.E. Kanoski, L.E. Rupprecht, and S.M. Fortin The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide Neuropharmacology 62 2012 1916 1927
24. A.J. Kastin, and V. Akerstrom Entry of exendin-4 into brain is rapid but may be limited at high doses Int. J. Obes. Relat. Metab. Disord. 27 2003 313 318
25. A.J. Kastin, V. Akerstrom, and W. Pan Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier J. Mol. Neurosci. 18 2002 7 14
26. A.E. Kelley, V.P. Bakshi, and S.N. Haber Opioid modulation of taste hedonics within the ventral striatum Physiol. Behav. 76 2002 365 377
27. K.P. Kinzig, D.A. D'Alessio, and R.J. Seeley The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness J. Neurosci. 22 2002 10470 10476
28. B. Kreymann, G. Williams, and M.A. Ghatei Glucagon-like peptide-1 7-36: a physiological incretin in man Lancet 2 1987 1300 1304
29. K. Madsen, L.B. Knudsen, and H. Agersoe Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness J. Med. Chem. 50 2007 6126 6132
30. P.L. McClean, V. Parthsarathy, and E. Faivre The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimers disease J. Neurosci. 31 2011 6587 6594
31. N.M. Neary, C.J. Small, and M.R. Druce Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively Endocrinology 146 2005 5120 5127
32. R. Nogueiras, A. Romero-Picó, and M.J. Vazquez The opioid system and food intake: homeostatic and hedonic mechanisms Obes. Facts 5 2012 196 207
33. P.K. Olszewski, J. Alsiö, and H.B. Schiöth Opioids as facilitators of feeding: can any food be rewarding? Physiol. Behav. 104 2011 105 110
34. C. Orskov, S.S. Poulsen, and M. Møller Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I Diabetes 45 1996 832 835
35. R.L. Prigeon, S. Quddusi, and B. Paty Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect Am. J. Physiol. Endocrinol. Metab. 285 2003 E701 E707
36. K. Raun, P. von Voss, and C.F. Gotfredsen Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not Diabetes 56 2007 8 15
37. F. Rodriquez de Fonseca, M. Navarro, and E. Alvarez Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats Metabolism 49 2000 709 717
38. A. Sainsbury, S. Lin, and K. McNamara Dynorphin knockout reduces fat mass and increases weight loss during fasting in mice Mol. Endocrinol. 21 2007 1722 1735
39. C. Schürmann, A. Linke, and K. Engelmann-Pilger The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice J. Pharmacol. Exp. Ther. 342 2012 71 80
40. R.J. Seeley, K. Blake, and P.A. Rushing The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride J. Neurosci. 20 2000 1616 1621
41. P.J. Shughrue, M.V. Lane, and I. Merchenthaler Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus Endocrinology 137 1996 5159 5162
42. M. Tang-Christensen, P.J. Larsen, and R. Göke Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats Am. J. Physiol. 271 1996 R848 R856
43. M. Tang-Christensen, N. Vrang, and P.J. Larsen Glucagon-like peptide 1(7-36) amides central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment Diabetes 47 1998 530 537
44. L. van Bloemendaal, J.S. Ten Kulve, and S.E. la Fleur Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS J. Endocrinol. 221 2014 T1 T16
45. T. Vilsbøll, T. Krarup, and J. Sonne Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus J. Clin. Endocrinol. Metab. 88 2003 2706 2713
46. T. Vilsbøll, M. Christensen, and A.E. Junker Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials Br. Med. J. 344 2012 d7771
47. N.D. Volkow, G.J. Wang, and R.D. Baler Reward, dopamine and the control of food intake: implications for obesity Trends Cogn. Sci. 15 2011 37 46
48. N. Vrang, P.J. Larsen, and J.T. Clausen Neurochemical characterization of hypothalamic cocaine-amphetamine-regulated transcript neurons J. Neurosci. 19 1999 RC5
49. D.L. Williams, D.G. Baskin, and M.W. Schwartz Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety Endocrinology 150 2009 1680 1687